Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma

Neurosurgery. 2017 Nov 1;81(5):N42-N43. doi: 10.1093/neuros/nyx449.

Authors

Julia R Schneider¹, Kevin Kwan¹, John A Boockvar^{1

2}

Affiliations

¹ Brain Tumor Center Department of Neurosurgery Lenox Hill Hospital & Hofstra Northwell School of Medicine New York, New York.
² New York Head and Neck Institute Hofstra Northwell School of Medicine New York, New York.

PMID: 29088463
DOI: 10.1093/neuros/nyx449

No abstract available